{"filing":{"accession_number":"0001093557-26-000167","cik":"0001093557","ticker":"DXCM","company_name":"DEXCOM INC","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-10","primary_document":"dxcm-20260910.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1093557/000109355726000167/dxcm-20260910.htm"},"events":[{"id":32674,"run_id":30035,"accession_number":"0001093557-26-000167","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"DexCom appointed Glenn S. Boehnlein as a director effective September 10, 2026, with assignment to the Operations \u0026 Innovation Committee and Audit Committee. Boehnlein brings extensive healthcare and finance leadership experience, including prior service as Vice President and Chief Financial Officer of Stryker Corporation.","company_name":"DEXCOM INC","ticker":"DXCM","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35904,"accession_number":"0001093557-26-000167","item_number":"5.02","item_title":"DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Glenn S. Boehnlein as a director of DexCom, effective immediately, with assignment to the Operations \u0026 Innovation Committee and Audit Committee. While the disclosure also includes compensatory details (RSU grants totaling $500,000 initial and $347,500 annual), the principal disclosed action is the appointment of a new director with significant healthcare and finance expertise. This is a material governance event affecting board composition and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:20:34.970233+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35905,"accession_number":"0001093557-26-000167","item_number":"7.01","item_title":"REGULATION FD DISCLOSURE.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Dexcom announced the appointment of Glenn Boehnlein to its Board of Directors effective September 10, 2026. The press release emphasizes his extensive healthcare and finance leadership experience, including his prior role as Vice President and Chief Financial Officer of Stryker Corporation, and notes that the Board conducted a deliberate search for an independent director with deep MedTech expertise. This is a material governance event affecting board composition and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:20:34.970233+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35904,"accession_number":"0001093557-26-000167","item_number":"5.02","item_title":"DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Glenn S. Boehnlein as a director of DexCom, effective immediately, with assignment to the Operations \u0026 Innovation Committee and Audit Committee. While the disclosure also includes compensatory details (RSU grants totaling $500,000 initial and $347,500 annual), the principal disclosed action is the appointment of a new director with significant healthcare and finance expertise. This is a material governance event affecting board composition and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:20:34.970233+00:00","company_name":"DEXCOM INC","ticker":"DXCM","filing_date":"2026-09-10"},{"id":35905,"accession_number":"0001093557-26-000167","item_number":"7.01","item_title":"REGULATION FD DISCLOSURE.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Dexcom announced the appointment of Glenn Boehnlein to its Board of Directors effective September 10, 2026. The press release emphasizes his extensive healthcare and finance leadership experience, including his prior role as Vice President and Chief Financial Officer of Stryker Corporation, and notes that the Board conducted a deliberate search for an independent director with deep MedTech expertise. This is a material governance event affecting board composition and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:20:34.970233+00:00","company_name":"DEXCOM INC","ticker":"DXCM","filing_date":"2026-09-10"}]}